Abstract No reliable marker has been identified to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer. A multicenter prospective study was conducted between 2012 and 2021. Patients with resectable cT3-4 gastric cancer were included.